The Reproducibility Problem Hidden in Your Pediatric Vision Trial
The U.S. FDA accepts ETDRS charts as the standardized protocol for adult clinical trial visual acuity endpoints. For pediatric trials, no equivalent mandate exists. That gap creates a serious problem.
When different sites in a multi-center pediatric trial use different optotypes (Snellen, HOTV, LEA SYMBOLS®), the resulting data are not directly comparable. A study of 59 amblyopic patients found a mean visual acuity difference of −0.056 logMAR between HOTV and LEA SYMBOLS®, slightly more than half a line on the chart. That difference is large enough to shift enrollment eligibility, alter outcome classifications, and undermine cross-site comparisons.
The stakes are substantial. Global amblyopia prevalence is estimated at 1.36%, representing roughly 99.2 million people in 2019 and projected to reach 221.9 million by 2040. Children screened before age 4 have a 90% success rate in achieving 20/20 vision; for those first diagnosed after age 7, that rate drops to 60%. The treatment window is narrow, and the measurement tools used during that window must be precise and consistent. LEA SYMBOLS® represent the field's strongest available solution to this reproducibility gap.
What Makes LEA SYMBOLS® Uniquely Calibrated for Research
LEA SYMBOLS® are the only picture optotypes calibrated against the internationally standardized Landolt C vision test symbol, making them directly traceable to ISO 8596, the global standard for visual acuity measurement. This traceability is a metrological property that gives researchers a defensible link to an internationally recognized reference, not a marketing claim.
The late Dr. Lea Hyvärinen designed the four optotypes (circle, square, apple/heart, and house) so that each symbol blurs equally at the threshold of vision. This equal-blur property ensures internal consistency across all four symbols, a prerequisite for valid acuity measurement. If one symbol were easier to identify than another near threshold, the test would introduce systematic error, exactly the kind of noise that erodes statistical power in clinical trials.
LEA charts were also the first pediatric eye charts built on a logarithmic (logMAR) scale. On a logMAR chart, each line represents a constant, proportional change in optotype size. This uniform scaling is critical for detecting small inter-ocular differences and for performing valid statistical analyses on visual acuity data. The World Health Organization endorses logMAR-based charts for vision screening, reflecting broad international consensus.
These three design properties (ISO traceability, equal blur, and logMAR scaling) combine to produce a measurement instrument with the internal consistency required for registered clinical trials. Without all three, a pediatric optotype chart is a screening tool, not a research instrument.
Regulatory and Guideline Endorsements That Matter for Protocol Design
The American Academy of Pediatrics (AAP) and the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) recommend only LEA SYMBOLS® or HOTV characters for preschool-aged vision screening. Snellen, Tumbling E, Allen Pictures, Landolt C, Lighthouse, and Kindergarten charts are explicitly excluded.
The 2025 NCCVEH (National Center for Children's Vision and Eye Health) guideline update, published in Optometry and Vision Science, confirmed that LEA SYMBOLS® and HOTV remain the only two optotypes meeting best-practice standards for children aged 3 to under 6. This update carries direct implications for researchers: IRB submissions, grant applications, and multi-site protocols that include pediatric vision endpoints must align with these updated standards to be considered methodologically sound.
The FDA gap remains. While ETDRS is accepted for adult trial registration, no formal pediatric equivalent exists. LEA SYMBOLS®' calibration to the Landolt C and logMAR design make them the closest available analog for researchers seeking defensible, standardized endpoints in pediatric populations.
A 2024 systematic review and meta-analysis published in JAAPOS, encompassing 7,948 patients, confirmed that LEA SYMBOLS® and HOTV are clinically comparable. Average testing time differences between the two were only 2 to 7 seconds, a statistically detectable but clinically negligible gap. For protocol designers, this means choosing LEA SYMBOLS® does not impose a meaningful time burden on young participants or clinical staff.
Evidence From Large-Scale Studies and Clinical Trials
Population-level data reinforces the research utility of LEA SYMBOLS®. A Croatian national registry study tested 58,712 four-year-olds with LEA SYMBOLS® inline optotypes, establishing normative visual acuity thresholds for this age group. Of those tested, 83.78% had unremarkable results and 16.22% were referred for further examination, with 92% of referrals due to binocular causes. A dataset of this size provides the normative benchmarks that clinical trial protocols need for enrollment criteria and outcome thresholds.
A 2025 Italian study of 1,500 children aged 5 to 15 used LEA SYMBOLS® as the measurement instrument and explicitly cited the need for uniform evaluation protocols. The authors noted that variability in screening criteria between countries and healthcare centers undermines reproducibility, a finding that underscores the value of a single, internationally calibrated optotype system.
The Vision in Preschoolers (VIP) Study Group found that more than 95% of children aged 3 to 5 successfully completed LEA SYMBOLS® screening, with no statistically significant differences in completion rates compared to HOTV. In a separate evaluation, a 15-line LEA folding chart correctly identified visual acuity in 95.9% of 149 preschool children across different screening environments.
Sensitivity data are equally compelling. In a randomized trial of 260 preschool children, the LEA SYMBOLS® chart demonstrated a sensitivity of 94.74%, compared to just 52.63% for the Sheridan-Gardiner chart — nearly double the detection rate for the same population.
Internationally, a 2024 study published in TVST/ARVO confirmed that LEA SYMBOLS® serve as the clinical reference standard in Germany's national guideline for amblyopia, illustrating their role as a de facto international benchmark beyond U.S. guidelines.
Good-Lite Co is also directly invested in expanding the evidence base. We are currently sponsoring a clinical trial (ClinicalTrials.gov NCT07081139) titled "Visual Function Screening System With Special Needs Children and Typical Preschoolers," actively investigating LEA SYMBOLS® in structured research contexts as of July 2026. We disclose this sponsorship transparently as part of our commitment to advancing pediatric vision science.
Special Populations and Emerging Research Frontiers
Children with autism spectrum disorder, cerebral palsy, Down syndrome, and intellectual disabilities are chronically underrepresented in vision trials. The reason is straightforward: letter-based charts require literacy and verbal response, which many of these children cannot provide. LEA SYMBOLS®' matching-card response method removes the literacy barrier entirely, allowing children to match what they see to a card they hold. This expands testable populations in research settings and makes inclusive trial design practical rather than aspirational.
The rise of digital therapeutics for amblyopia, including binocular gaming apps and other software-based treatments, creates urgent demand for standardized pediatric VA endpoints. The Amblyopia Treatment Study (ATS) protocol, widely used as the primary outcome standard in these trials, relies on single-bar flanked letter acuity, a format acknowledged to overestimate VA. LEA SYMBOLS® crowded linear formats offer a more accurate alternative for research outcomes.
AI and machine learning applications in pediatric vision screening, such as eye-tracking-based amblyopia detection, require validated ground-truth VA measurements to train and test their algorithms. LEA SYMBOLS® provide the standardized reference data these systems need. Similarly, the expansion of telehealth-based pediatric vision research benefits from LEA SYMBOLS®' standardized format and matching-card protocol, which are more adaptable to supervised remote testing than letter-based alternatives.
Why Optotype Standardization Is the Linchpin of Reproducible Pediatric Research
In multi-site and multinational trials, optotype non-standardization inflates measurement error, reduces statistical power, and makes cross-study meta-analyses unreliable. The evidence presented throughout this article points to a single conclusion: LEA SYMBOLS®' calibration to the Landolt C and logMAR scaling make them the only picture optotype capable of bridging inter-site variability in pediatric research.
The quantitative stakes bear repeating. A 0.056 logMAR difference between optotypes exceeds half a line, enough to shift a child from eligible to ineligible, or from treatment success to treatment failure, in a clinical trial. The normative data infrastructure built on LEA SYMBOLS®, including the Croatian registry of 58,712 children, provides the reference benchmarks that clinical trial enrollment criteria and outcome thresholds depend on.
As the exclusive manufacturer of physical LEA® systems and a trusted leader in vision testing since 1930, Good-Lite Co maintained a longstanding partnership with the late Dr. Lea Hyvärinen to bring these instruments to clinicians and researchers worldwide. If you are designing a pediatric vision protocol, submitting to an IRB, or selecting outcome measures for a grant application, specify LEA SYMBOLS® by name. The reproducibility of your data depends on it.
